论文部分内容阅读
目的探讨吉非替尼治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法将我院2010年1月至2013年12月收治的120例晚期非小细胞肺癌患者随机分为两组,对照组采用常规化疗,观察组使用吉非替尼治疗。结果观察组有效率为48.3%,明显优于对照组有效率的11.7%,两组比较差异有统计学意义(P<0.05)。随访3~12个月,观察组中位疾病进展时间(6.8±1.3)个月,中位生存期(7.4±0.5)个月,对照组中位疾病进展时间平均(4.8±0.6)个月,中位生存期平均(5.7±0.6)个月,差异有统计学意义(P<0.05)。结论吉非替尼作为一种有效治疗晚期NSCLC的靶向药物,可有效提高患者的生存期和生活质量,具有较好的耐受性和安全性。
Objective To investigate the clinical efficacy of gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 120 patients with advanced non-small cell lung cancer admitted to our hospital from January 2010 to December 2013 were randomly divided into two groups. The control group received conventional chemotherapy and the observation group received gefitinib treatment. Results The effective rate of the observation group was 48.3%, which was significantly better than that of the control group (11.7%). There was significant difference between the two groups (P <0.05). The median duration of disease progression in the observation group was (6.8 ± 1.3) months and the median survival time was (7.4 ± 0.5) months. The mean progression time of the median disease in the control group was 4.8 ± 0.6 months, The median survival time was (5.7 ± 0.6) months on average, the difference was statistically significant (P <0.05). Conclusion Gefitinib can effectively improve the survival and quality of life of patients with advanced NSCLC as a targeted drug with good tolerance and safety.